Benazepril HCl 40 mg Tablets, Fed

NCT ID: NCT00836537

Last Updated: 2023-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-03-31
• Study Completion Date: 2001-03-31

Brief Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in healthy adult volunteers under non-fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

Benazepril HCl 40 mg Tablets

Intervention Type: DRUG

1 x 40 mg, single-dose fed

2

Group Type: ACTIVE_COMPARATOR

Lotensin® 40 mg Tablets

Intervention Type: DRUG

1 x 40 mg, single-dose fed

Interventions

Benazepril HCl 40 mg Tablets

1 x 40 mg, single-dose fed

Intervention Type: DRUG

Lotensin® 40 mg Tablets

1 x 40 mg, single-dose fed

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Screening Demographics: All volunteers for selected for this study will be healthy men or women 19 years of age or older at the time of dosing. The weight range will not exceed ±20% for height and body frame as per Desirable Weights for Men - 1983 Metropolitan height and Weight Table or as per Desirable Weights for Women - 1983 Metropolitan Height and Weight Table. Subjects must have a minimum weight of at least 110 pounds.
• Screening procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.

Screening will include general observations, physical examination, demographics, medical and medication history, a 12-lead electrocardiogram, sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.

• The screening clinical laboratory procedures will include:

1. Hematology: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet count;

2. Clinical Chemistry: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total bilirubin, total protein, and alkaline phosphatase;

3. HIV antibody, hepatitis B surface antigen, and hepatitis C antibody screens;

4. Urinalysis: by dipstick; full microscopic examination if dipstick positive; and

5. Urine Drug Screen: ethyl alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolites, opiates and phencyclidine.

6. Serum Pregnancy Screen (female volunteers only)

• If female and:

1. of childbearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, sponge, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

2. is postmenopausal for at least 1 year; or

3. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy

Exclusion Criteria

• Volunteers with a recent history of drug or alcohol addiction or abuse in the past 24 months.
• Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined bt the medical investigator).
• Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
• Volunteers demonstrating a positive hepatitis B surface antigen screen, hepatitis C antibody screen or a reactive HIV antibody screen.
• Volunteers demonstrating a positive drug abuse screen when screened for this study.
• Female volunteers demonstrating a positive pregnancy screen.
• Female volunteers who are currently breastfeeding.
• Volunteers with a history of allergic response(s) to benazepril hydrochloride or related drugs.
• Volunteers with a history of clinically significant allergies including drug allergies.
• Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the medical investigator).
• Volunteers who currently use tobacco products. Three months abstinence is required.
• Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to Period I dosing.
• Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
• Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weks after completing the study.
• Volunteers who report receiving any investigational drug within 30 days prior to period I dosing.
• Volunteers who report taking any prescription medication in the 14 days prior to Period I dosing and no OTC medications within 7 days prior to Period I dosing.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

James D. Carlson, Pharm. D.

Role: PRINCIPAL_INVESTIGATOR

PRACS Institute, Ltd.

Locations

PRACS Institute, Ltd.

Fargo, North Dakota, United States

Countries

United States

Other Identifiers

R01-050

Identifier Type: -

Identifier Source: org_study_id